Burjeel announces depemokimab administration for rhinosinusitis with nasal polyps
Burjeel Medical City in Abu Dhabi says it has administered depemokimab to a patient with chronic rhinosinusitis with nasal polyps. The announcement, carried by WAM on 6 November 2026, describes the use as a Gulf first.
According to the hospital, the 43-year-old Emirati patient had experienced persistent symptoms for more than five years despite two operations. Burjeel describes a subcutaneous injection with a six-month dosing interval, administered with support and oversight from Abu Dhabi’s Department of Health.
WAM and Al-Ittihad repeat information supplied by the hospital; they are not two independent clinical assessments. The announcement documents reported use without publishing follow-up that establishes this patient’s outcome. Regional priority remains Burjeel’s claim.